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Abstract — Chronic Kidney Disease (CKD) is an increasingly 
prevalent condition affecting 13% of the US population. The 
disease is often a silent condition, making its diagnosis 
challenging. Identifying CKD stages from standard office visit 
records can help in early detection of the disease and lead to timely 
intervention. The dataset we use is highly imbalanced. We propose 
a hierarchical meta-classification method, aiming to stratify CKD 
by severity levels, employing simple quantitative non-text 
features gathered from office visit records, while addressing data 
imbalance. Our method effectively stratifies CKD severity levels 
obtaining high average sensitivity, precision and F-measure 
(~93%). We also conduct experiments in which the dimensionality 
of the data is significantly reduced to include only the most salient 
features. Our results show that the good performance of our 
system is retained even when using the reduced feature sets, as well 
as under much reduced training sets, indicating that our method 
is stable and generalizable. 
Keywords—Imbalanced Data; Biomedical Informatics;  
Meta-classification; EHR; Chronic Kidney Disease 
I. INTRODUCTION 
Chronic kidney disease (CKD) is an increasingly prevalent 
condition affecting 13% of the US population [1]. It is defined 
as kidney damage that persists for more than three months, and 
is typically stratified into five stages, 1-5, indicating increasing 
order of severity [2]. CKD severity is quantified by estimated 
glomerular filtration rate (eGFR) [3], an indicator of the level 
of kidney function. Stage 1 is defined by kidney damage  
(protein or blood in the urines) while eGFR is normal  
(eGFR ≥90 ml/min/1.73m2); stage 2 by kidney damage and 
mildly decreased eGFR (eGFR 60-<90); stage 3 as eGFR  
30-<60; stage 4 as eGFR 15-<30 and stage 5 as eGFR <15. The 
eGFR measure is estimated from serum creatinine lab tests, 
race, sex and age. CKD patients, especially those at stages 4 and 
5, are at high risk of end stage renal disease (ESRD) or death if 
their condition is not diagnosed [1]. However, because CKD, 
even in its advanced stages, is often asymptomatic, serum 
creatinine lab tests are often not ordered, resulting in the 
condition remaining undiagnosed.  
According to a report by the Kidney Early Evaluation 
Program (KEEP) [1], among 122,502 program participants 
enrolled at the time of the study, fewer than 30% of patients at 
stages 4 and 5 had ever seen a nephrologist. However, 95% of 
these patients had visited a general practitioner during the year 
preceding the study, for a condition other than CKD. Hence, a 
risk stratification model that separates CKD patients into 
severity stages based on information gathered during office 
visits can alert physicians about the advanced stages (stages 4-
5) of the condition, and prompt them to urgently order the 
appropriate lab tests confirming the diagnosis. 
According to treatment guidelines, patients at CKD stage 4 
should be referred to a nephrologist and be prepared for renal 
replacement therapy [3]. The latter typically includes 
hemodialysis, which patients often begin with only a short 
notice, and thus without the benefit of a functional arteriovenous 
fistula, which needs to be surgically created several months prior 
to hemodialysis initiation. Recent data from the United States 
Renal Disease System (USRDS) show that only 17% of patients 
initiating hemodialysis do so with a functional arteriovenous 
fistula [4]. Finally, given the increasing focus on population 
health management, identifying patients at high risk for end 
stage renal disease from Electronic Health Records (EHRs), 
may be helpful for case-managers that are often responsible for 
the health of thousands of individuals. Hence, in this study, we 
aim to stratify CKD patients into severity stages (CKD stages  
3-5), based on clinical information gathered during office visits. 
In collaboration with physicians from Christiana Care 
Health System, the largest health-system in Delaware, we 
analyze a dataset gathered over a period of nine years from 
13,111 patients. It comprises 120,739 records obtained during 
patients’ visits to multiple primary care and specialty practices 
across Delaware, which are part of the information stored in 
EHRs. Patient records were selected for inclusion in the dataset 
if at any time during follow-up, there was an indication of a 
decline in kidney function, determined by a lower than normal 
eGFR value (<60), indicative of CKD at stage 3 or higher. The 
resulting dataset includes all records of patients associated with 
stages 3, 4 and 5. Each record in the dataset comprises 495 
simple quantitative non-text attributes summarizing the patient’s 
demographics, vital signs, medications and diagnosed 
conditions. We use the values of these attributes as features to 
represent each patient’s visit record. Notably, unlike physicians’ 
notes, these 495 non-text attributes are available for the vast 
majority of patients, and their semantics is unambiguous and 
readily interpretable. The dataset is described in Section II. 
While EHRs provide valuable patient health information for 
patient risk-stratification and disease prediction, one of the 
major challenges in using them arises from data imbalance. That 
is, only a small proportion of patients suffer from the more 
severe conditions, while most patients suffer only a milder 
manifestation of the disease. Specifically, in our dataset, the 
number of records associated with stage 3 is 10 times larger than 
the number of records associated with stage 4, and 23 times 
larger than that of stage 5. Imbalanced datasets, whose class 
distribution is skewed, form a common challenge in data mining 
applications, such as fraud or disease detection, where the class 
of interest is heavily underrepresented compared to the other 
classes. As noted later in this section, learning classifiers using 
off-the-shelf packages from such an imbalanced dataset 
typically leads to poor performance.  
We thus propose and develop a supervised machine learning 
method that addresses data imbalance, while aiming to stratify 
CKD patients already identified as advanced, into severity 
stages (stages 3-5), using information gathered from standard 
office visit records. Taking advantage of such standard records 
supports a generalizable approach, applicable to most patients 
who regularly see a healthcare provider.  
Additionally, to extract from the records the most 
informative features indicative of decline in kidney function, we 
conduct feature selection using Least Absolute Shrinkage and 
Selection Operator (LASSO) regression [5], a regularized linear 
regression method that assigns a weight of 0 to less informative 
features, ensuring that only relevant features are taken into 
account in the classification. 
Several recent studies proposed approaches for patient risk-
stratification and disease prediction using machine learning 
methods [6-10]. For instance, Mani et al. [6], aimed to predict 
diabetes risk based on lab results, diagnosed conditions and 
medications, using six simple classification methods, including 
naïve Bayes and decision trees. Similarly, Ogunyemi et al. [7] 
added insurance information and vital signs, while aiming to 
predict risk of diabetic retinopathy using an ensemble classifier, 
based on decision tree learners. The authors use random under-
sampling of the majority class to address data imbalance. 
Teixeira et al. [8] also used similar information while including 
narrative text aiming to predict hypertension using the random 
forest classifier. Unlike our study, none of the above is based 
solely on simple quantitative attributes in office visit records; 
they instead use lab test results, insurance information and 
narrative text, in addition to office visit records. Moreover, all 
three studies were based on only very small datasets  
(< 2,300 records), while ours is an order of magnitude larger. 
Last, while aiming to conduct prediction, the training set in these 
studies was not limited to temporally early records while 
restricting the test set to later records, as we do here. As such, 
these studies do not actually demonstrate predictive power.  
In a significantly larger study (n≈35,000), Huang et al. [9] 
aimed to predict depression severity and patient's  response to 
treatment, using free-text clinical reports in addition to office 
visit records. Like we do here, they too employ the LASSO 
regression for feature selection and prediction. However, they 
do not directly address class imbalance that is inherent in the 
dataset, as we do here, and their reported performance stands at 
50% sensitivity at the time of diagnosis and 25% sensitivity 12 
months prior to diagnosis.  
To the best of our knowledge, ours is the first study aiming 
to identify disease stage exclusively using simple quantitative 
attributes obtained from office visit records, while also directly 
addressing the class imbalance among different severity levels. 
Data imbalance is often handled in machine learning via 
sampling strategies [11-17]. Typically, these involve either 
under-sampling – reducing the size of the majority class by 
removing instances from the training set, or over-sampling – 
increasing the impact of the minority class, by sampling from it 
with repetition. Several previous studies have proposed variants 
of under/over-sampling approaches to address class imbalance. 
Examples include one-sided selection [11] and synthetic 
minority oversampling technique (SMOTE) [12].  
Notably, most of these are concerned with binary 
classification, while ours is a multiclass task, as we are looking 
to assign one of three possible stages to each record (possibly 
more in future studies).  
Two approaches commonly used to transform multi-class 
classification into multiple binary-classification tasks are one-
against-all (OAA) and one-against-one (OAO) [13]. Tan et al. 
[14] use both these schemes in the context of protein fold 
classification, and subsequently build rule-based learners to 
improve coverage of the minority class. Zhao et al. [15] use OAA 
to handle multiclass classification, while employing under-
sampling and SMOTE techniques on imbalanced data, for 
protein classification. Another approach to address class 
imbalance is using cost sensitive ensemble methods [16].  
Before developing our own approach, we have applied 
versions of the above methods, specifically, random over- and 
under-sampling, and over-sampling using SMOTE and 
ADASYN. None has improved on the results obtained by simple 
classifiers that do not account for class imbalance (to which we 
refer as baseline classifiers), such as simple random forest. 
Thus, as mentioned earlier, we developed a supervised machine 
learning method, hierarchical meta-classification, that aims to 
separate CKD stages 3, 4 and 5, while addressing data 
imbalance. The method frames the multiclass classification task 
as a sequence of two subtasks. The first is binary classification, 
separating records associated with stage 3 from those associated 
with a combined class consisting of stages 4 and 5, using  
meta-classification. Meta-classification combines results 
obtained from multiple simple classifiers (base-classifiers) into 
a single classification decision [18]. The second subtask 
separates the records assigned to the combined stages 4 and 5 
class into the individual classes.  
To train the hierarchical meta-classifier, we take advantage 
of the earlier visit records, gathered between the years 2007-
2014, while testing is done based on later records, gathered 
during 2015. We also trained the hierarchical meta-classifier on 
a dataset represented by only the informative attributes 
identified through feature selection, and compared the 
performance to that obtained when the complete set of features 
was used. We evaluate the performance of our methods using 
standard metrics, namely, overall accuracy, as well as 
specificity, sensitivity, precision and F-measure [5]. The results 
demonstrate that our hierarchical meta-classifier trained on a 
dataset represented via the complete set of features, improves 
upon multiple baselines, showing a performance level of about 
93% according to almost all evaluation measures, along with an 
average specificity of 77%. The good performance of our 
method indicates that simple quantitative attributes from office 
visit records can form the basis for CKD severity detection and 
stratification. Our results also indicate that our method retains its 
high performance level even when trained on a dataset 
represented via a reduced feature set. Furthermore, to assess the 
medical validity of our results we verify that the features 
identified as pertinent by the feature selection process are indeed 
indicative of CKD severity according to the medical literature.  
To further demonstrate the predictive ability of our method, 
we progressively reduced the training set size by truncating the 
early years of patient history, one year at a time, yielding 8 
training sets. The test set was fixed to be the records collected in 
2015, which ensures that the training set always comprises 
temporally earlier records than the test set. We show that 
classification remains as effective when the number of years 
(and of visit records) included in the patient history and used by 
the classifier is reduced, illustrating the stability and 
generalizability of our hierarchical meta-classifier. 
II. DATASET 
Our dataset comprises 120,739 records obtained during 
patients’ visits to multiple primary care and specialty practices 
across Delaware; these records form part of the information 
stored in EHRs. As mentioned earlier, records were included in 
the dataset if they indicated a decline in kidney function, 
determined by a lower than normal eGFR value  
(< 60 mL/min/1.73m2), indicating CKD of stage 3 or higher.  
We removed from the dataset 27,521 records that were 
missing essential values, leaving a set of 93,218 complete 
records, where 60% are associated with female patients and 40% 
with male. The average number of visits per patient, over the 9 
year period, is 9; the patients’ mean age is 70 (σ =12.4), and the 
range is 18-107, where 70% of the patients are 58-82. Table 1 
shows the four categories of features comprising the dataset, 
along with the number of actual features per category. 
Information pertaining to the features listed in Table 1 is 
routinely collected and stored in the EHR during each visit to the 
general practitioner, making our approach broadly applicable to 
office visit records beyond the specific disease and dataset 
analyzed here. 
Given our aim of stratifying CKD by severity, we have 
removed five of the 495 features that are directly reflective of 
CKD from our feature set. The five features denote five 
diagnosed CKD conditions, namely: CKD stage 2, CKD stage 
3, CKD stage 4, End Stage Renal Disease and Chronic Renal 
Failure. We thus use a total of 490 features for representing the 
patients’ records in our dataset. Specifically, each record, 
ݎ௞ (1 ≤ k ≤ 93,218), is represented as a 490-dimensional vector, 
ܸ௞ =< ݒଵ௞, … , ݒସଽ଴௞ >, where each dimension corresponds to 
one of the 490 features.  
As noted in Section I, our dataset is highly imbalanced, as is 
often the case in a biomedical setting, where the outcome of 
interest, in our case, stages 4 and 5, is rare, and thus 
underrepresented. In our study, the ratio among the number of 
records associated with each of the stages 3, 4 and 5 is 23:2:1 
respectively. Recall that we progressively reduced the training 
set size by pruning the early years of patient history, one year at 
time, yielding 8 training sets. Table 2 shows the number of 
records per class, for each of the 8 training sets. The table also 
shows the number of records per stage collected in 2015 and 
used as the test set.  
III. METHODS 
We next describe the hierarchical meta-classifier we have 
developed, including the feature selection method and the 
baseline and simple meta-classifier used for comparison. 
Feature Selection: Building classifiers from a large feature 
set can lead to over-fitting. We thus conduct feature selection 
to determine the most relevant attributes for CKD stratification 
using LASSO regression [5], a modified form of least squares 
regression that penalizes model complexity via a regularization 
parameter by assigning zero weights to less informative 
features. For training the regression model, we use eGFR values 
instead of CKD stages as the response variable, since eGFR is 
a continuous numeric variable. The salient features predictive 
of eGFR are also informative of CKD severity-levels, since the 
latter are calculated from eGFR values. We use the Python 
scikit-learn package [19] for applying LASSO regression. 
Baseline Classifiers: As a baseline for comparison, we use 
four standard methods, namely, logistic regression, naïve 
Bayes, decision tree and random forest, employing the one-
against-all strategy to assign a CKD stage to each office visit 
record. We use the Python scikit-learn implementation for 
training the four classifiers [19].  
TABLE 1. FOUR CATEGORIES OF FEATURES COMPRISING OUR DATASET. THE LEFTMOST COLUMN SHOWS THE CATEGORIES, WHILE THE MIDDLE COLUMN SHOWS THE 
NUMBER OF FEATURES PER CATEGORY. THE RIGHTMOST COLUMN SHOWS EXAMPLES OF FEATURES ASSOCIATED WITH EACH CATEGORY.  
Category Number of Features Examples 
Demographics 
 
Vital Signs 
 
Diagnosed Conditions 
4 
 
4 
 
454 
Gender; Age; Ethnicity; Race 
 
Heart Rate; Systolic and Diastolic Blood Pressure, Body Mass Index 
 
Benign essential hypertension; Type 2 diabetes mellitus; Obesity 
Medications 33 ACE Inhibitors; Alpha Beta Blocker; Insulin  
 
TABLE 2. NUMBER OF RECORDS IN EACH OF THE CLASSES WITHIN THE 8 TRAINING SETS OBTAINED BY PROGRESSIVELY TRUNCATING THE EARLY YEARS OF PATIENT 
HISTORY INCLUDED IN THE TRAINING DATA. THE RESPECTIVE YEAR RANGE IS SHOWN IN THE SECOND ROW. THE LEFTMOST COLUMN SHOWS CKD STAGES. THE 
RIGHTMOST COLUMN SHOWS THE NUMBER OF RECORDS PER STAGE, COLLECTED IN 2015 AND USED AS THE TEST SET. EACH OF THE OTHER COLUMNS SHOWS THE 
NUMBER OF RECORDS PER STAGE FOR THE CORRESPONDING TRAINING SET, COLLECTED DURING THE PERIOD INDICATED IN THE SECOND ROW. 
CKD 
Stages 
TRAINING SET DISTRIBUTION TEST SET 
2007-2014 2008-2014 2009 - 2014 2010-2014 2011-2014 2012-2014 2013-2014 2014 2015 
Stage 3 73,425 72,808 70,127 65,326 57,863 46,881 33,072 17,273 8,419 
Stage 4 6,976 6,903 6,579 6,060 5,385 4,439 3,101 1,624 782 
Stage 5 3,241 3,184 3,052 2,821 2,515 2,068 1,471 767 375 
Total 83,642 82,895 79,758 74,207 65,763 53,388 37,644 19,664 9,576 
 
 
Meta-Classification: To separate CKD stages 3–5, while 
addressing data imbalance, we employ meta-classification, 
which aims to assemble results obtained from multiple 
classifiers into a single classification outcome. The approach 
comprises two sub-tasks: First, a set of M simple classifiers, 
{C1,…,CM	} are trained, and applied to each visit record, rk, 
where the latter is represented as a 490-dimensional vector, 
<ݒଵ௞ ,…, ݒସଽ଴௞ > as described above. We refer to the simple 
classifiers as base-classifiers. Each of these classifiers assigns a 
label ܥ௝௞	(ܥ௝௞	∈ {3,4,5}) to the vector Vk. Second, the class 
labels assigned by the M simple classifiers are used to re-
represent the visit record rk as an M-dimensional vector  
<ܥଵ௞  ,…	ܥெ௞>. This representation is then used to train a meta-
classifier that assigns the final class label to each record [18].  
To train the base-classifiers, we produce balanced training 
sets by first partitioning the data stemming from the over-
represented classes into smaller subsets. Specifically, as the 
ratio among the number of records associated with each of the 
stages 3, 4 and 5 is 23:2:1 respectively, we partition the stage 3 
set into 23 equal subsets and the stage 4 set into two equal 
subsets. Each subset contains the same number of records as 
that included in the stage 5 set. Next, we combine each of the 
stage 3 subsets with the stage 5 set and with one of the two stage 
4 subsets that we select at random, thus forming a total of 23 
datasets, each having a uniform distribution across the three 
CKD stages. Fig. 1 illustrates the data partitioning scheme. 
To choose the base classifier, from among four commonly 
used simple classifiers, namely logistic regression, naïve Bayes, 
decision tree and random forest, we conducted four sets of 
experiments, in each we employed one of these methods as a 
base classifier. We trained each of the four classifier types on 
the 23 sets, thus generating 23 base-classifiers per type. Using 
each set of 23 base-classifiers, we trained a meta-classifier in 
which the training set was re-represented as 23-dimensional 
vectors (M=23), where the value along the ith dimension 
consists of the label obtained from the ith base-classifier when 
applied to the original record representation. In all four sets of 
experiments the meta-classifier used is a naïve Bayes classifier, 
as it proved to perform best, and has proven effective by others 
as well [20]. 
Hierarchical Meta-Classification: As CKD stage 3 (eGFR 
range of 30–60) is characterized by moderately reduced kidney 
function, while stages 4 and 5 (eGFR < 30) are characterized by 
severely reduced kidney function [1], records associated with 
patients at stages 4 and 5 are likely to be more similar to one 
another than to records of patients at stage 3. Thus, the simple 
meta-classifier introduced above often fails to separate between 
stages 4 and 5, while also misclassifying stage 3 records. 
Therefore, we introduce hierarchical meta-classification, which 
first separates records associated with stages 4 and 5 from those 
associated with stage 3, and then further separates the combined 
class consisting of stages 4 and 5 records into the two individual 
subclasses. To separate the stage 3 class from the combined 
stage 4 and 5 class we use the meta-classification scheme 
described above. We then employ multiple simple classifiers 
(including random forest and naïve Bayes), to separate the 
combined stage 4 and 5 set into the two respective stages. The 
simple random forest classifier is most effective in separating 
stage 4 from stage 5 patients.  
Fig. 2 summarizes the hierarchical meta-classification 
approach, where the top dashed-square corresponds to the 
coarse high-level classification, separating stage 3 from the 
combined stages 4 and 5 records, while the bottom dashed-
square depicts the refinement step, separating the combined 
class into the refined stage 4 and stage 5 classes.  
To train the base-classifiers for the coarse classification step 
(distinguishing stage 3 from the combined two other stages), we 
first partition the data using a similar scheme to that shown in 
Fig. 1, albeit partitioning the records associated with stage 3 
into only 7 parts (rather than 23) as there are only 7 times more 
records associated with stage 3 than with the combined set of 
stages 4 and 5. We next train the 7 respective base-classifiers, 
re-represent the datasets as described when discussing meta-
classification above, and train a naïve Bayes meta-classifier 
using the re-represented data. The resulting classifier aims to 
separate stage 3 records from records that are stage 4 or 5  
(see Fig. 2A).  
To train the random forest classifier for the refinement step 
(separating the combined class into individual stage 4 and stage 
5 records, see Fig. 2B), we use the set of records from the 
training data that are associated with stages 4 and 5. 
To test the meta-classifiers, each record in the test set is 
classified by each of the base-classifiers, and the labels obtained 
from each of these base classifiers are used to form a feature 
vector, which becomes the input to the meta-classifier. The 
meta-classifier is applied to each newly represented vector, thus 
separating stage 3 records from records of stages 4 or 5. Records 
classified into the combined stage 4 and stage 5 class in the 
coarse classification step, are further categorized by the simple 
random forest classifier in the refinement step, and assigned to 
either the stage 4 or stage 5 individual class. 
 
 
Figure 1. Data partitioning scheme for meta-classification. The set of stage 3 records is partitioned into 23 subsets (white squares in the figure). That of stage 4 is 
partitioned into two subsets (grey squares and lined squares), where each subset contains the same number of records as that included in the stage 5 set (black 
squares). We combine each of the stage 3 subsets with the stage 5 set and with one of the two stage 4 subsets that we select at random, thus forming a total of 23 
datasets, each having a uniform distribution across the three stages. 
. 
Figure 2. Hierarchical meta-classification for multiclass classification. A. Coarse classification: The dashed rectangle represents the meta-classification scheme used 
for separating stage 3 records from those associated with either stage 4 or stage 5. The white oval represents the set of records assigned to the combined class by the 
meta-classifier, while the shaded ovals represent the final classes corresponding to the individual three stages. B.  Refinement step: The combined set of stage 4 and 
5 records is separated into individual respective constituent subsets. The rhombus represents a simple random forest classifier. 
IV. EXPERIMENTS 
As a baseline, we first trained and tested simple naïve Bayes, 
logistic regression, decision tree, and random forest classifiers 
using the complete set of 490 features to represent each record. 
Next, to address the data imbalance, we applied both meta-
classification and hierarchical meta-classification to the 
records. For each of the four methods, we used records from the 
first 8 years (2007- 2014) for training, and the ninth year (2015) 
for testing. Notably, we did not use cross-validation for training 
and testing our methods, since we limited the training set to 
temporally early records (from the first 8 years, 2007-2014) 
while restricting the test set to later records (from the ninth year, 
2015). To ensure stability of the results, we employ multiple 
random splits to partition the training set stemming from the 
over-represented class into smaller subsets for training the base-
classifiers in the coarse classification stage (see Fig. 2B) of the 
hierarchical meta-classifier, while keeping the test set fixed to 
all records from 2015. 
After each classification step, we evaluated the performance 
using standard measures, namely, overall accuracy, sensitivity, 
specificity and F-measure. We compared the performance 
attained from the four classifiers as baseline and as a component 
of the simple and the hierarchical meta-classifiers, to assess 
their respective efficacy in separating CKD stages. As noted in 
Section I, we also applied other methods such as random over- 
and under-sampling and SMOTE to address data imbalance and 
found the performance of hierarchical meta-classification to be 
the best. Hence, we focus here only on the results obtained 
using hierarchical meta-classification. 
We next employed feature selection using LASSO, to 
identify the features most indicative of CKD stages. Once the 
features were selected, we represented patients using the 
reduced feature set, and repeated the classification experiments 
to assess the impact of the reduced number of features on 
performance. We compared the results obtained from the 
classifiers trained on the dataset represented through the 
complete feature set with those obtained from the classifiers 
trained using the reduced representation.  
Last, we examined the performance of our method when the 
number of years (and of visit records) included in the patient 
history and used by the classifier, is reduced. To do so, we 
repeated the experiments using the hierarchical meta-
classification while progressively truncating the early years of 
patient history included in the training data, one year at a time, 
yielding 8 sets of training data. As in previous experiments, we 
kept the test set fixed to records collected in 2015. The first set 
included records gathered between the years of 2007 and 2014, 
yielding a training set containing 83,642 records, while the 
eighth set included data collected in 2014 alone, yielding a 
training set of 19,664 records. We trained the hierarchical meta-
classifier over each of the training sets, using both a record 
representation employing the complete set of 490 features, and 
one employing only the reduced feature set. This set of 
experiments assessed the generalizability of our approach, i.e. 
its ability to assign the correct severity level based only on the 
most recent history of the patient. 
Recall that to ensure the stability of our model, we repeated 
each experiment 20 times, using different splits to partition the 
set of records associated with the over-represented class. 
V. RESULTS  
The hierarchical meta-classifier, the baseline classifiers and 
the simple, non-hierarchical meta-classifier perform 
significantly better when decision tree or random forest 
classifiers are used – either alone as baseline classifiers, or in 
an assemblage of base-classifiers within a meta-classifier – as 
compared to logistic regression or naïve Bayes. We thus report 
here only results obtained using decision tree and random 
forest, as standalone baseline classifiers and as components 
within meta-classification. Fig. 3 shows the average specificity, 
sensitivity and F-measure, obtained by the hierarchical meta-
classification scheme, compared to those obtained by each of 
the baseline classifiers and by the simple, non-hierarchical 
meta-classifier for decision tree and random forest methods. 
The average is calculated as a weighted-average, taking into 
account the class-size associated with each of the three stages. 
Fig. 4 shows the sensitivity and F-measure per-class, attained 
by the random forest baseline classifier and by the random 
forest hierarchical meta-classifier.  
Our feature selection process identified 119 of the 490 
features as most informative of CKD severity-levels. Table 3 
lists 18 of the 119 salient features (due to limited space), across 
the four categories of features comprising the dataset. Table 4 
shows a comparison between the performance of the 
hierarchical meta-classifier trained on the reduced-
dimensionality dataset, represented via the selected 119 
features, against that of the classifier trained on the dataset 
represented via the complete feature set. 
The above results were obtained from experiments 
conducted on records dated 2007-14 used for training, while 
records from 2015 were used for testing. Fig. 5 shows the True 
Positive Rates (TPR) and False Negative Rates (FNR) per-class 
for the 8 training sets (see Table 2) that were obtained by 
progressively truncating the early years of patient history in the 
training data, one year at time. We used each of the 8 sets to 
train the random forest hierarchical meta-classifier, using the 
complete feature set. The average accuracy, specificity, 
sensitivity, precision and F-measure are all about 0.93  
(std < 0.03) for all 8 sets.  
As described in Section IV, we repeated all experiments 20 
times using multiple random splits. We obtained similar results 
in all runs (std << 0.03).  
VI. DISCUSSION 
The hierarchical meta-classifier that employs random forest 
base-classifiers (denoted RF-Hier-MC in Fig. 3) outperforms 
all other classifiers according to all measures except for 
specificity (0.77), which is lower than that of the simple, non-
hierarchical random-forest-based meta-classifier (0.85, 
classifier denoted RF-MC in Fig. 3). Accuracy and precision, 
both 0.93, are not shown in the figure due to limited space. We 
also note that the performance of the baseline random forest 
classifier (denoted RF-Baseline) is similar to that of the random 
forest hierarchical meta-classifier (denoted RF-Hier-MC) in 
terms of average sensitivity and F-measure. However, as shown 
in Fig. 4, the performance of the two classifiers varies 
significantly across CKD stages. 
 
 
Figure 3. Average specificity, average sensitivity and average F-measure of the decision tree (DT) and random forest (RF) baseline classifier (Baseline), meta-
classifier (MC) and hierarchical meta-classifier (Hier-MC) for assigning CKD severity stages (3-5) to patient’s office visit records. Classifiers were trained on office 
visit records from 2007-14 using the complete features set (490 features) to represent patients, while records from 2015 were used as the test set. The X-axis shows 
the classifier used; the Y-axis shows the average specificity, sensitivity and F-measure for each of the classifiers.  
        
Figure 4. Performance per-class in terms of Sensitivity (left plot) and F-measure (right plot), of the random forest baseline classifier (RF-Baseline) and of the random 
forest hierarchical meta-classifier (RF-Hier-MC). The X-axes of both plots show CKD stages; the Y-axes show sensitivity and F-measure per CKD stage. 
Clearly, the hierarchical meta-classifier shows a much higher 
sensitivity and F-measure for both stages 4 and 5 than the 
baseline classifier, indicating that the hierarchical meta-
classifier identifies advanced CKD stage records (stages 4 and 
5) more effectively than the baseline. Fig. 3 and Fig. 4 both 
demonstrate that hierarchical meta-classification outperforms 
the baseline and the simple meta-classifier for identifying CKD 
stages 4 and 5.  
We note that in the context of risk-stratification, and 
particularly when assigning an advanced stage label to a record, 
false negatives (i.e. missing a severe case) have much more 
severe implications than false positives (assigning a stage 4 or 
5 label to a stage 3 case). That said, having a very large portion 
of false-positives is clearly undesirable as it generates false 
alarms. We further examine these points by calculating the 
precision, (also referred to as positive predictive value, PPV) 
and the sensitivity for the set of records associated with the 
combined stage 4 and 5 records. Precision penalizes for false 
positives, while sensitivity penalizes for false negatives.  
The precision of the classification with respect to the 
combined set is 0.68. That is, of the 1,157 records classified as 
stages 4 or 5 by the hierarchical meta-classifier in our test set, 
787 are correctly identified. It is important to note that of the 
remaining 370 false-positive records, 181 (~50%) are 
borderline cases, as indicated by eGFR values in the range of 
30-44, which is associated with patients suffering from 
advanced stage 3 CKD (stage 3b) [21]. Recent studies 
demonstrate that stage 3b is the inflection point for adverse 
outcomes, including progression to end stage renal disease 
(stage 5) [22]. Thus, the random forest hierarchical meta-
classifier effectively identifies not only the advanced stage 
records already marked, but also the likely-to-be severe cases 
that are not yet labeled as such. As for the sensitivity, Fig. 4 
clearly shows that hierarchical meta-classifier has a much 
higher sensitivity for stages 4 and 5 records than the baseline, 
while retaining about the same sensitivity as the baseline with 
respect to stage 3. 
To verify that the features detected as pertinent by our 
feature selection method are indeed known to be predictive of 
CKD severity-levels, we conducted a survey of the medical 
literature. The survey suggests that most of the features 
identified by LASSO regression are known to be indicative of 
kidney disease, providing validation that our feature selection 
identifies attributes that are expected to be predictive of CKD 
severity-levels [2,22]. For instance, conditions such as 
Congestive Heart Failure, Type 2 Diabetes Mellitus and 
Anemia, which the method identifies as informative, are widely 
known to be associated with kidney disease [2, 22].  
Our results from the experiments in which only the 119 
selected features were used, (Tables 3,4) demonstrate that even 
for the reduced feature set, our method shows high average 
accuracy, sensitivity, precision and F-measure values of 0.92. 
Notably, the difference between the results obtained when using 
119 features and those obtained when using the complete set of 
490 features, according to all five measures, is very small. The 
consistent high performance values of our model when trained 
on a reduced feature set, indicates that the identified features 
are indeed highly informative of CKD.  
Moreover, the high performance values obtained from the 
random forest hierarchical meta-classifier when trained on the 
datasets obtained by progressively truncating the early years of 
patient history, one year at time, indicate that the model 
effectively identifies CKD stages even when it is trained on 
limited, recent patient history. As can be seen from Fig. 5, the 
true-positive rate remains constant, regardless of the number of 
years included in the visit record, except for a slight decline in 
predicting stages 4 and 5 when using data from 2013/14 or 2014 
alone. The false-negative rate is not impacted by the reduction 
in a patient’s history.  
Our results thus indicate that training our model on limited 
patient history does not significantly affect performance. 
Similar results were also obtained when the number of features 
was reduced. The consistent good performance of our method 
for datasets of different sizes containing patients’ visit records 
gathered over different year ranges, indicates our model’s 
stability and generalizability, and highlights its applicability in 
clinical settings, where old records are not always available to 
train the model.  
TABLE 3. EXAMPLES OF 18 OF THE 119 FEATURES IDENTIFIED AS INFORMATIVE OF CKD STAGES BY OUR FEATURE SELECTION METHOD, LASSO REGRESSION.  
Category Example Features 
Demographics  Age; Gender; Race 
Vital Signs Body Mass Index; Systolic Blood Pressure; Diastolic Blood Pressure 
Medications Insulin Response Enhancers Biguanides; Direct Acting Vasodilators; Insulin; ACE Inhibitors ; Beta Blockers Cardiac Selective; Alpha Beta Blockers; Antihyperglycemic Dipeptidyl Peptidase 4 Inhibitors 
Diagnosed Conditions Congestive Heart Failure; Type 2 Diabetes Mellitus; Anemia; Erythrocyte sedimentation rate raised; Benign Essential Hypertension; Degenerative joint disease of pelvis 
TABLE 4. COMPARISON OF RANDOM FOREST HIERARCHICAL META-CLASSIFIER (RF-HIER-MC) TRAINED ON DATASETS REPRESENTED VIA 119 FEATURES AND A 
CLASSIFIER TRAINED ON A DATASET REPRESENTED VIA 490 FEATURES. STANDARD DEVIATION IS SHOWN IN PARENTHESES.  
Classifier Accuracy Specificity Sensitivity Precision F-measure 
RF-Hier-MC (119 features) 0.92 (0.02) 0.74 (0.03) 0.92 (0.02) 0.92 (0.02) 0.92 (0.02) 
RF-Hier-MC (490 features) 0.93 (0.02) 0.77 (0.02) 0.93 (0.02) 0.93 (0.02) 0.93 (0.02) 
 
Figure 5. True Positive Rates, TPR (solid plots) and False Negative Rates, FNR (dashed plots) with respect to stages 3, 4 and 5, associated with eight hierarchical 
meta-classifiers, each trained on datasets obtained by gradually truncating the early years of patient history included in the training set, one year at a time. The  
X-axis shows the years covered by each training set. The Y-axis shows the true positive rate (top) or false negative rate (bottom). 
VII. CONCLUSION 
We have shown, using a large collection of office visit 
records gathered from many thousands of patients, that CKD 
severity-levels can be effectively stratified using simple 
quantitative attributes collected during standard office visits, in 
the face of imbalanced data. We developed a hierarchical meta-
classifier to assess CKD stages from highly imbalanced training 
sets, achieving average accuracy, sensitivity, precision and  
F-measure of 0.93. Our method significantly outperforms 
baseline classifiers and simple meta-classifiers in identifying 
advanced CKD stages (stages 4 and 5). Our results also show 
that the method retains its good performance when the feature 
set is reduced, as well as when the number of records is 
significantly truncated.  
As a future direction, we plan to evaluate the efficacy of the 
method in separating patient records not associated with kidney 
disease or those associated with less-severe stages, from those 
associated with severe stages. We also expect that our method 
can be applied to attain severity stratification in other health 
conditions using standard office visit records. 
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